NEW YORK, May 16, 2017 /PRNewswire/ --
According to a research by New Frontier Data, the legal cannabis market was worth an estimated $7.2
billion in 2016. The medical market is projected to grow at 13% CAGR through 2025, growing from $4.7 billion in 2016 to an estimated $13.3 billion in 2020. During the same
period, adult-use sales are projected to grow at a 25% CAGR, from $2.6 billion to $11.2 billion.
The report indicates the projections are based on assumptions that no other states will legalize cannabis use throughout the
forecast period. As expected from a new growing market, the legal cannabis industry is projected to become a major job creating
merchantry. "These numbers confirm that cannabis is a major economic driver and job creation engine for the U.S. economy," said
Giadha Aguirre De Carcer, Founder and CEO of New Frontier Data. ChineseInvestors.com, Inc. (OTC: CIIX), Zynerba
Pharmaceuticals Inc. (NASDAQ: ZYNE), Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), Eco Science Solutions, Inc. (OTC:
ESSI), General Cannabis Corporation (OTC: CANN)
One major component of the legal cannabis industry is the CBD market. A report by the The Hemp Business Journal estimates
that the CBD market will grow to a $2.1 billion market in consumer sales by 2020 with $450 million of those sales coming from hemp-based sources. In 2015, the market for consumer sales of
hemp-derived CBD products were $90 million, plus another $112 million
in marijuana-derived CBD products, sold through dispensaries - bringing a total CBD market to $202
million last year. That's a 700% increase from 2016.
ChineseInvestors.com, Inc. (OTCQB: CIIX) announced on May 2nd that it has appointed
Summer (XiangYang) Yun as Chief Executive Officer (CEO) of its wholly-owned foreign entity, CBD
Biotechnology Co., Ltd. XiBiDi Biotech's primary focus is online, retail and direct sales of hemp-based health products in
China. Yun's initial focus will be the launch of 'CBD Magic Hemp Series' cosmetics line. He will
also spearhead the Company's plan to import natural dietary supplements created using advanced extracting and purifying
technologies into China. Yun is a marketing and branding executive with over 25 years of
experience. Yun will report directly to CIIX's CEO Warren Wang.
"I am honored to be named as CEO of CBD Biotech," says Yun. "For over 5,000 years, hemp has been cultivated and used in over
25,000 products worldwide. CIIX has a unique opportunity to become one of the first companies to offer CBD-based skin care
products in China online and through established retail and direct selling channels. Through the
introduction of Magic CBD Series cosmetics to China, I hope to educate consumers regarding
hemp's many benefits."
The CBD Magic Hemp Series line will include cleansers, moisturizing lotions and anti-aging products created using
supercritical CO2 extraction technology. CBD Biotech also plans to launch a series of oral spray vitamins and supplements that
can be used for relaxation, pain relief and sleep, among other things. Yun will oversee marketing and sales of these products in
China, and utilizing his branding and marketing expertise, he will work to grow the CBD Biotech
brand.
"I believe Yun is the perfect candidate to oversee CBD Biotech's operations. I am confident in his ability to introduce this
revolutionary CBD-based skin care line to China and create and generate substantial revenue for
CIIX," says Wang.
Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) dedicates to developing next-generation synthetic cannabinoid
therapeutics for transdermal delivery for patients with high unmet medical needs. On March 13,
2017, the company announced that it has completed enrollment in the Phase 2 STAR 1 (Synthetic Transdermal Cannabidiol
for the Treatment of Epilepsy) clinical trial evaluating ZYN002 cannabidiol (CBD) gel in adult epilepsy patients with refractory
focal seizures. The Company also announced that enrollment has completed in the Phase 2 STOP (Synthetic Transdermal
Cannabidiol for the Treatment of Knee Pain due to Osteoarthritis) clinical trial evaluating ZYN002 CBD gel for the treatment
of osteoarthritis.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) recently announced that subject enrollment is complete in its
Phase 2 clinical study of anabasum (formerly known as JBT-101) for the treatment of skin-predominant dermatomyositis. The Company
expects topline results from this study to be available in the fourth quarter of 2017. Anabasum is a first-in-class, synthetic
oral endocannabinoid-mimetic drug that preferentially binds to the cannabinoid receptor type 2 (CB2) receptor expressed on
activated immune cells and fibroblasts. CB2 activation triggers endogenous pathways that resolve inflammation and halt
fibrosis.
Eco Science Solutions, Inc. (OTCQB: ESSI) is a technology-focused company targeting the health, wellness and
alternative medicine industry. Recently, the company announced that it has signed a Sponsorship, Content Development and
Licensing agreement with Roaring Lion Tours, Inc. to develop unique educational content that brings awareness and education to
the alternative medicine category. Roaring Lion Tour develops inspirational and educational content that further promotes
the benefits of medical marijuana. "There is a continuing need to bring awareness to the benefits of medical marijuana as a key
category in the alternative medical health industry," stated Jeff Taylor, Chief Executive Officer
of Eco Science Solutions.
General Cannabis Corporation (OTCQB: CANN) is the comprehensive resource for the highest quality service providers
available to the regulated Cannabis Industry. Recently, the company announced financial results for the quarter ended
March 31, 2017. In the first quarter, the company reported a 4% increase in total revenues when
compared to the quarter ended March 31, 2016. During the first quarter of 2017, the company's
Operations segment, Next Big Crop, increased revenues by 119% over the first quarter of 2016. "Next Big Crop, our Operations
segment, had record revenues in the first quarter of 2017," said Robert Frichtel, Chief Executive
Officer of General Cannabis.
Please Sign Up Now at http://www.FinancialBuzz.com to Receive
Alerts on Trending Financial News from all these companies. 'The Latest Buzz in Financial News'
Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News,
Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company
Interviews. A pioneer in the financially driven digital space, video production and integration of social media,
FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination,
branding, marketing and advertising for third parties for corporate news and original content through our unique media platform
that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial
Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not
undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "Site") is either original financial news or paid advertisements provided
[exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into
service agreements with the companies which are the subject to the articles posted on the Site or other editorials for
advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the
information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting
high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com
does not offer any personal opinions as we purely incorporate public market research along with financial and corporate news.
FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media
platform. We also do not include any personal opinions or commentary. For this release, FinancialBuzz.com expects to be
compensated three thousand dollars for financial news dissemination and pr services by
chineseInvestors.com inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on
this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement
and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com has signed a two year agreement with
chineseinvestors.com inc. for one hundred thousand restricted common shares for continued financial news dissemination and pr
services. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR
advertising. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information
about any companies the information contained herein is not intended to be used as the basis for investment decisions and should
not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to
buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result
from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes
electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own
independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By
accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended
from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase,
hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor.
This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular
security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and
tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions.
We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to
change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not
guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com
For further information:
Media Contact:
info@financialbuzz.com
+1-877-601-1879
Url: http://www.FinancialBuzz.com
SOURCE FinancialBuzz.com